Primary plasma cell leukemia in the era of new drugs: Has something changed?

Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, Fortunato Morabito, Tommaso Caravita, Francesco Di Raimondo, Luca Baldini, Patrizia Tosi, Sara Bringhen, Massimo Offidani, Paola Omede', Antonino Neri, Fiorella D'Auria, Giovanni Battista Bochicchio, Michele Cavo, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticle

Abstract

Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disease is associated with a very poor prognosis, and unfortunately it has not significantly improved during the last three decades. Autologous stem cell transplantation is generally recommended in eligible patients, but survival in transplanted PPCL patients is significantly lower than that of multiple myeloma. Recent preliminary data indicate that new drugs, in particular lenalidomide and bortezomib, could significantly improve the clinical outcome of PPCL, increasing response rate and duration, as well as survival. In this review we report an updated literature analysis about the current therapeutic scenario of PPCL, with a particular focus on the use of novel agents.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume82
Issue number2
DOIs
Publication statusPublished - May 2012

Keywords

  • Bortezomib
  • Lenalidomide
  • Myeloma
  • Plasma cell leukemia
  • Stem cell transplantation
  • Thalidomide

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Primary plasma cell leukemia in the era of new drugs: Has something changed?'. Together they form a unique fingerprint.

  • Cite this

    Musto, P., Pagano, L., Petrucci, M. T., Morabito, F., Caravita, T., Di Raimondo, F., Baldini, L., Tosi, P., Bringhen, S., Offidani, M., Omede', P., Neri, A., D'Auria, F., Bochicchio, G. B., Cavo, M., Boccadoro, M., & Palumbo, A. (2012). Primary plasma cell leukemia in the era of new drugs: Has something changed? Critical Reviews in Oncology/Hematology, 82(2), 141-149. https://doi.org/10.1016/j.critrevonc.2011.04.005